Newly listed stock has 27% upside potential! JM Financial issues buy call; Check target price and key triggers
60-Word AI Digest
JM Financial initiated coverage of Symbiotec Pharmalab with a Buy rating and a ₹1,622 target price, implying about 27% upside. It expects new capacity, CDMO and complex injectable growth to lift revenue, EBITDA and profit through FY29.
Key Takeaways
- JM Financial initiated coverage of Symbiotec Pharmalab with a Buy rating and a ₹1,622 target price, implying about 27% upside.
- It expects new capacity, CDMO and complex injectable growth to lift revenue, EBITDA and profit through FY29.
- Full details and original dispatch available below.
JM Financial initiated coverage of Symbiotec Pharmalab with a Buy rating and a ₹1,622 target price, implying about 27% upside. It expects new capacity, CDMO and complex injectable growth to lift revenue, EBITDA and profit through FY29.
Original Publisher Attribution
This summary was curated from Livemint.